Pfizer Announces $10 Billion Share Repurchase Program

Pfizer Inc. (PFE), the world’s biggest drugmaker, said it will buy back $10 billion in stock after earlier this week announcing it will retire about $11.4 billion in shares through the spinoff of its animal-health unit.

The buyback is the fourth major share repurchase program for New York-based Pfizer in the past 2 1/2 years. During that time, the company has announced $39 billion in share buybacks, including today’s. Pfizer has $3.9 billion left on its current repurchase program, the company said today in a statement.

Ian Read, Pfizer’s chief executive officer, has said that share repurchases are the best uses of Pfizer’s cash, compared with acquisitions or increasing the dividend. Read has shed non-drug units to focus on developing and selling new, brand-name therapies. The company, which had a market capitalization of about $200 billion as of today’s close, is looking at whether it will split itself and get rid of its generics drug business.

Pfizer earlier this week announced the completion of a deal to exchange shares of its own stock for equity in Zoetis Inc. (ZTS), its former animal-health unit. That exchange is expected to retire about $11.4 billion in Pfizer shares.

Pfizer shares gained 1.4 percent to $28.58 in extended trading at 5:35 p.m. New York time after the buyback was announced. The company’s stock has increased 25 percent in the past 12 months.

To contact the reporter on this story: Drew Armstrong in New York at;

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.